Mon Oct 06 11:40:00 UTC 2025: **Trump Administration Announces Drug Pricing Deal with Pfizer, Unveils Direct-to-Consumer Website**
**Washington D.C.** – In a move touted as a significant step toward lowering prescription drug costs for Americans, the Trump administration announced a deal with Pfizer to align Medicaid drug prices with those in European countries. Additionally, officials unveiled plans for a website, TrumpRx.gov, designed to facilitate direct drug purchases from manufacturers.
The Pfizer agreement will see the pharmaceutical giant charge Medicaid the same prices it charges European nations, and potentially serve as a precedent for other medications and insurance types.
Trump officials are urging manufacturers to set prices for newly introduced drugs at similar levels in the United States and other rich countries.
While officials celebrated the deal and the forthcoming website as major victories for patients, some experts remain skeptical of the impact, asserting that the measures may only benefit a small segment of the population.
“It’s a really good way to say you’re doing something about drug prices, and not actually do anything to change the underlying profits of the industry,” said Stacie Dusetzina, a health policy professor at Vanderbilt University.
The TrumpRx.gov website is intended to guide consumers to manufacturers’ direct-to-consumer sales programs. These programs, already in use by companies like Eli Lilly and Novo Nordisk, primarily target drugs not typically covered by insurance, such as obesity medications.
Critics point out that most Americans rely on insurance to fill prescriptions, limiting the website’s utility. Furthermore, the direct-to-consumer approach might not be the most cost-effective for many patients, as options like GoodRx and Mark Cuban Cost Plus Drugs Company often offer lower prices, particularly for generic medications.
Despite the uncertainty surrounding the new initiatives, the Trump administration hopes the Pfizer deal and TrumpRx.gov will mark a turning point in addressing the ongoing issue of high drug prices in the United States.
First Piper 